samedan logo
 
 
 
spacer
home > ebr > summer 2003 > perspectives in preclinical development
PUBLICATIONS
European Biopharmaceutical Review

Perspectives in Preclinical Development

Pharmaceutical companies have traditionally outsourced a proportion of their preclinical development studies to contract research laboratories. This co-operation can be traced back to the mid-sixties and the proliferation of regulatory guidelines which followed the thalidomide disaster earlier that decade. At that time, the international requirements for protocol-driven toxicity studies for new pharmaceuticals put a strain on the resources of many drug companies.

The answer for many was to outsource individual studies to the rapidly-evolving contract research industry, pioneered by companies such as Huntingdon Research Centre in England and Inveresk Research in Scotland. These organisations turned their focus from experimental nutrition studies to the toxicity testing of drugs and other chemicals.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Thomas Allen, Director of Allen Preclinical Consultants GmbH

Thomas Allen is a Director of Allen Preclinical Consultants GmbH, based in Switzerland. His career has spanned more than 25 years with European CROs and pharmaceutical companies, most recently with RCC Ltd where he was a member of the Executive Committee and, for many years, Director of Toxicology.

Thomas has a degree in Zoology and Physiology from the University of Sheffield and is a Diplomate of the Royal College of Pathologists and a European Registered Toxicologist.

spacer
Thomas Allen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ICON Releases Environmental, Social and Governance Report

ICON announced today the release of its 2020 Environmental, Social and Governance (ESG) Report.
More info >>

White Papers

Risk-Based Inspection Readiness: Reducing Headaches with Advanced Preparation

The Avoca Group

So often, inspections are a major source of stress in the clinical trial environment. This is especially true when processes involved in preparing for an inspection are reactive. But, it doesn’t have to be that way. Using industry-leading practices and resources enables a proactive approach to mitigate—or even eliminate—the pain points associated with preparing for inspections.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement